Asthmatx Breathes Easier
Four-year old Asthmatx aims to be the first device company in asthma, a multi-billion dollar drug market. Asthmatx has run its Alair device, which reduces smooth muscle in the lung, through several clinical trials with an eye toward giving a choice to people suffering from the severest forms of the disease.
You may also be interested in...
Pulmonary Device Companies Take It To The Streets - In Europe
For the past decade, venture capitalists have invested in companies that are developing new technologies to treat late-stage chronic obstructive pulmonary disorders.Despite hundreds of millions in venture capital dollars, the companies have made little progress in bringing these products to market in the US. But this band of start-ups is taking the fight to the streets - of Europe.
Asthmatx Acquisition By Boston Scientific Is Source of Many Happy Returns
Boston Scientific's acquisition of Asthmatx marks a return of the company to the field of strategic buyers with the deal, and in picking Asthmatx, BSX is is reversing a decision it made two years when it sold off its strategic stake in the asthma-device company.
Asthmatx Following the Leaders In Defining Alair Sales Strategy
Asthmatx is adopting the commercial strategy of high profile successes including Kyphon, Acclarent, Novacept, Fox Hollow Technologies to roll out its Alair broncial thermoplasty system, which recently received approval from the FDA.